South San Francisco-based Akero Therapeutics presented results from a 16-week analysis of secondary and exploratory endpoints in the company’s Phase IIa BALANCED clinical trial of efruxifermin in nonalcoholic steatohepatitis (NASH).
If you are not happy with the results below please do another search
50 search results for:
New U.S. COVID-19 cases rose by nearly 50,000 on Wednesday, according to a Reuters tally, marking the biggest one-day spike since the start of the pandemic.
The U.S. Justice Department charged Glenmark Pharmaceuticals with conspiring with other generic drug companies to increase and hold prices for the cholesterol drug pravastatin between May 2013 and December 2015.
Another pandemic may be building in China as a new strain of the H1N1 swine flu has already jumped to humans.
New York-based Pfizer and Germany-based BioNTech announced preliminary data from the most advanced of four vaccine candidates against SARS-CoV-2, the virus causing COVID-19.
Americans’ anxieties over the spread of the coronavirus are at the highest in more than a month, a Reuters/Ipsos poll showed on Wednesday, as California recorded the state’s largest single-day spike in cases since the pandemic began.
The U.S. Food and Drug Administration approved Bavencio (avelumab) for maintenance treatment of locally advanced or metastatic urothelial carcinoma that has not progressed after first-line platinum-containing chemotherapy.
A federal appeals court upheld two patents for Amgen’s multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis’ effort to void the patents.
This webinar will share information on the influence of multimillion-dollar pharmaceutical costs, along with successful cost containment practices demonstrated through case studies of effective intervention.
Treatments for peanut allergy and Parkinson’s disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show.